SCHEMBL21169293

SCHEMBL21169293

CCN1CCCC(C(=O)Nc2ccccc2)C1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 1/20 0.61
OGA O60502 1/20 0.59
HPGD P15428 2/20 0.57
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
CARM1 Q86X55 1/20 0.54
PRMT6 Q96LA8 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HTT P42858 1/20 0.52
MAPT P10636 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
GAA P10253 2/20 0.51
POLB P06746 1/20 0.51
USP2 O75604 1/20 0.50
YAP1 P46937 1/20 0.50
TEAD4 Q15561 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21652000 0.92 CARM1 (0.64) DRD3HPGDKMT2AMEN1CARM1
SCHEMBL5870879 0.83 DRD3 (0.77) DRD3OGAHPGDKMT2ACARM1
SCHEMBL20148033 0.83 CARM1 (0.71) OGAHPGDKMT2AMEN1CARM1
SCHEMBL14874212 0.82 PKM (0.63) DRD3HPGDKMT2AMEN1CARM1
SCHEMBL19002751 0.82 PKM (0.63) DRD3HPGDKMT2AMEN1CARM1
SCHEMBL15031310 0.79 DRD3 (0.49) DRD3KMT2AMEN1ALDH1A1GAA
SCHEMBL16076618 0.78 HPGD (0.57) OGAHPGDKMT2AMEN1CARM1
SCHEMBL18997929 0.78 HPGD (0.57) OGAHPGDKMT2AMEN1CARM1
SCHEMBL1553646 0.78 CYP3A4 (0.69) DRD3OGAHPGDKMT2AMEN1
SCHEMBL486205 0.77 KMT2A (0.65) HPGDKMT2ACARM1PRMT6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11026930-B1 Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease SHY Therapeutics LLC (US) 2021-06-08 US disclosed
US-10870657-B2 Compounds for the treatment of cancer and inflammatory disease SHY Therapeutics LLC (US) 2020-12-22 US disclosed
US-20190218229-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE SHY Therapeutics LLC 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218229-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE MAPK1, MAPK6, MAP3K1 DRD3 4791/4885OGA 1441/4885HPGD 253/4885
US-10870657-B2 Compounds for the treatment of cancer and inflammatory disease MAPK6, MAP3K6, MAPK4 DRD3 4860/4885OGA 1155/4885HPGD 365/4885
US-11026930-B1 Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease HRAS, KRAS, NRAS DRD3 4841/4885OGA 1969/4885HPGD 2278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.